Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Acquisitions & Divestments: 2022-2025

Historic Change in Acquisitions & Divestments for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $33.2 million.

  • Stoke Therapeutics' Change in Acquisitions & Divestments rose 65.76% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year increase of 115.30%. This contributed to the annual value of $60.0 million for FY2024, which is 44.22% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Change in Acquisitions & Divestments of $33.2 million as of Q3 2025, which was down 0.24% from $33.2 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Change in Acquisitions & Divestments ranged from a high of $79.0 million in Q3 2022 and a low of $9.0 million during Q1 2022.
  • Its 3-year average for Change in Acquisitions & Divestments is $26.7 million, with a median of $27.2 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 491.67% in 2023, then slumped by 81.22% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $18.0 million in 2022, then declined by 16.80% to $15.0 million in 2023, then spiked by 100.00% to $30.0 million in 2024, then skyrocketed by 65.76% to $33.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $33.2 million in Q3 2025, compared to $33.2 million in Q2 2025 and $32.8 million in Q1 2025.